Savara (SVRA) Income towards Parent Company (2010 - 2026)
Savara (SVRA) reported Income towards Parent Company of -$37.9 million for Q1 2026, down 42.4% year-over-year from -$65.9 million in Q1 2025, and down 17.72% quarter-over-quarter from -$32.2 million in Q4 2025.
Savara (SVRA) Income towards Parent Company (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Income towards Parent Company data on file, last reported at -$37.9 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$37.9 million, down 42.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$130.4 million (down 27.52% YoY), and the FY2025 annual result was -$119.4 million, down 23.42% from the prior year.
- Income towards Parent Company declined to -$37.9 million in Q1 2026 per SVRA's latest filing, from -$32.2 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$8.6 million in Q1 2022 and troughed at -$37.9 million in Q1 2026.
- A 5-year average of -$20.4 million and a median of -$20.3 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company climbed 21.72% in 2022, then sank 92.13% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at -$10.3 million in 2022, then plunged by 57.01% to -$16.1 million in 2023, then sank by 81.62% to -$29.3 million in 2024, then declined by 10.13% to -$32.2 million in 2025, then retreated by 17.72% to -$37.9 million in 2026.
- Business Quant data shows SVRA's Income towards Parent Company at -$37.9 million in Q1 2026, -$32.2 million in Q4 2025, and -$29.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.93 Mn |
| Dec 31, 2025 | -32.22 Mn |
| Sep 30, 2025 | -29.71 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.26 Mn |
| Sep 30, 2024 | -24.23 Mn |
| Jun 30, 2024 | -22.12 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.11 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -11.51 Mn |
| Mar 31, 2023 | -11.35 Mn |
| Dec 31, 2022 | -10.26 Mn |
| Sep 30, 2022 | -10.38 Mn |
| Jun 30, 2022 | -9.67 Mn |
| Mar 31, 2022 | -8.62 Mn |
| Dec 31, 2021 | -11.20 Mn |
| Sep 30, 2021 | -10.54 Mn |
| Jun 30, 2021 | -11.01 Mn |